Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 31;10(1):e003312. doi: 10.1136/jitc-2021-003312

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Clinical course and ctDNA, CEA and CA 19-9 monitoring. (A–D) Case #1, (E–H) Case #2, and (I–L) Case #3 patient clinical course and biomarker levels over time are represented. (A, E, I) Patient plots, providing details on the timeline of treatments administered, PET/CT scanning, and ctDNA monitoring. (B, F, J) ctDNA, (C, G, K) CEA and (D, H, L) CA 19-9 levels over time are represented, measured in number of days since surgical resection of the primary tumor. PET and CT scans, relapse, surgery, and therapeutic treatment windows are represented. CA, carbohydrate antigen; CEA, carcinoembryonic antigen; ctDNA, circulating tumor DNA; MTM, mean tumor molecules; PD, progressive disease; PET/CT, positron emission tomography/computed tomography;; PR, partial response; SD, stable disease 5FU, 5-fluorouracil,